...Kotone Hayuka; Hiroyuki Okuyama; Akitsu Murakami; Yoshihiro Okita; Takamasa Nishiuchi; Keiichi Okano; Yasuyuki Suzuki; Akihito Tsuji Introduction: Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established...

...: This phase II study was conducted to evaluate the efficacy and safety of the chemotherapy combination of gemcitabine and vinorelbine in taxane-pretreated Japanese metastatic breast cancer patients. Methods: In this multicenter, phase II, single-arm study, patients with recurrent or metastatic HER2-negative...

...-related issues. Methods: We collected data from 27 MBC patients treated with gemcitabine and oxaliplatin (GEMOX) at our institution between June 2009 and April 2015. The patients were heavily pretreated, and all had previously been exposed to anthracyclines and taxanes. Results: We achieved a complete...

... followed by the GDP (gemcitabine, dexamethasone and cisplatin) regimen. A favorable consolidative effect of the GDP regimen could be observed in the patient who had partial remission after administration of mogamulizumab monotherapy. The regimen showed an acceptable toxicity profile without serious...

... cancer who developed SCLE after administration of gemcitabine. Following discontinuation of gemcitabine and after oral steroid treatment, all skin lesions disappeared. In view of the extensive use of gemcitabine in recurrent ovarian cancer, it is important to be aware of the possibility of SCLE...

... and safety of the gemcitabine plus capecitabine combination chemotherapy. Methods: Sixty-four patients were enrolled. Treatment consisted of gemcitabine 1,000 mg/m 2 intravenously on days 1 and 8, plus oral capecitabine at 1,250 mg/m 2 twice daily on days 1-14. The primary end point was the overall response...

...Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myoung Hee Kang; Haa-Na Song; Anna Lee; Un Seok Lee; Hye Jung Choi; Hoon-Gu Kim Background: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced...

...Huapyong Kang; Jee Suk Chang; Tak Geun Oh; Moon Jae Chung; Jeong Youp Park; Seung Woo Park; Jinsil Seong; Si Young Song; Jae Bok Chung; Seungmin Bang Objectives: To compare the efficacy of full-dose gemcitabine-based concurrent chemoradiotherapy (FG-CCRT) and conventional 5-fluorouracil CCRT (5FU...

...Yukihiro Hasegawa; Dai Miura; Chiho Kitamura; Takaya Suzuki; Kazuma Kobayashi; Nobuyuki Sato Objective: Gemcitabine combined with carboplatin (GC) is a widely used regimen for advanced non-small cell lung cancer (NSCLC), but clinical outcome is still hampered by its toxicity. We conducted...

...François Ghiringhelli; Veronique Lorgis; Julie Vincent; Sylvain Ladoire; Boris Guiu Background: The aim of this study was to evaluate the efficacy and tolerability of hepatic arterial infusion (HAI) of gemcitabine plus oxaliplatin as second-line treatment for unresectable locally advanced...

...Sang Myung Woo; Woo Jin Lee; Ji Hun Kim; Dong Hwan Kim; Sung-Sik Han; Sang-Jae Park; Tae Hyun Kim; Ju Hee Lee; Young Hwan Koh; Eun Kyung Hong Background and Aim: Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC). We compared...

...Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Naminatsu Takahara; Dai Akiyama; Hiroshi Yagioka; Hirofumi Kogure; Saburo Matsubara; Yukiko Ito; Natsuyo Yamamoto; Naoki Sasahira; Kenji Hirano; Nobuo Toda; Minoru Tada; Kazuhiko Koike Background: To evaluate the treatment outcome of gemcitabine...

... of erlotinib combined with capecitabine and gemcitabine in the treatment of advanced pancreatic cancer (APC). Methods: Gemcitabine was administered intravenously at 1,000 mg/m 2 /week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m 2 /day. Oral erlotinib was administered daily...

...Kiyoshi Mori; Yukari Kamiyama; Hisashi Kasai; Tetsuro Kodama Background: The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). Methods: 46 chemotherapy-naive patients with measurable...

...Fumio Imamura; Makoto Nishio; Rintaro Noro; Masahiro Tsuboi; Norihiko Ikeda; Akira Inoue; Yoshinobu Ohsaki; Yukio Kimura; Kazumi Nishino; Junji Uchida; Takeshi Horai Background: Gemcitabine combined with carboplatin (CG) is one of the regimens used widely for advanced non-small cell lung cancer...

... II trial was to evaluate the efficacy and safety of a combination therapy with gemcitabine and irinotecan as the first-line chemotherapy in patients with previously untreated advanced BTC. Patients and Methods: Patients with pathologically confirmed advanced BTC received gemcitabine (1,000 mg/m 2...

... in gemcitabine (GEM)-resistant pancreatic cancer cells and that it suppressed the cytotoxic effect of GEM on the cells. This report describes the benefits of a treatment strategy combining the HSP inhibitor KNK437 with GEM for GEM-resistant pancreatic cancer cells. Methods: We used 2 human pancreatic cancer cell...

... treatment with gemcitabine (GEM), 9 patients GEM combined with radiotherapy (GEM+R) and 24 patients had best supportive care (BSC). We analyzed survival rates among the groups and risk factors for each group. Results: The 3-year survival rates were dismal: GEM group 2.9%, GEM+R group 0% and BSC group 0...

...L. Chelis; N. Xenidis; K. Amarantidis; P. Prassopoulos; E. Chamalidou; K. Neanidis; D. Mikroulis; E. Chatzaki; P. Karakitsos; S. Kakolyris Background: To evaluate the activity and tolerance of gemcitabine (GEM) in combination with vinorelbine (VRL) in pretreated patients with advanced non-small...

...Simona Ricciardi; Valentina Mey; Sara Nannizzi; Giuseppe Pasqualetti; Francesco Crea; Mario Del Tacca; Romano Danesi Background: Current treatments have a modest impact on survival of pancreatic cancer patients and this study investigates the interaction between sorafenib and gemcitabine...